Skip to main content
Erschienen in:

26.07.2022 | original article

Optical biometric measurements in patients with previous COVID-19 treatment

verfasst von: Tugba Çetinkaya, MD, Muhammed Mustafa Kurt, MD

Erschienen in: Spektrum der Augenheilkunde | Ausgabe 4/2023

Einloggen, um Zugang zu erhalten

Summary

Background

We aimed to compare optical biometric measurements using optical biometry in patients with previously received COVID-19 treatment and a control group.

Methods

In this cross-sectional study, patients with previously received COVID-19 treatment formed the COVID-19 group and age- and sex-matched healthy participants formed the control group. Optical biometric measurements including keratometry, corneal astigmatism, astigmatic axis, central corneal thickness, anterior chamber depth, and axial length were made using a Nidek optical biometer (AL-Scan; Nidek Co., Ltd., Japan).

Results

Measurements of keratometry (p = 0.79), corneal astigmatism (p = 0.41), axial length (p = 0.96), anterior chamber depth (p = 0.59), and central corneal thickness (p = 0.37) were similar between the COVID-19 and control groups. The astigmatic axis type taken from 2.4 mm of the cornea showed significant difference between the two groups (p = 0.02, χ2), while the measurements taken from 3.3 mm of the cornea were similar (p = 0.10, χ2). In the subgroup analysis, axial length, anterior chamber depth, and central corneal thickness measurements were found to be statistically significantly higher in male patients of the COVID-19 group (p = 0.02; p = 0.001; p = 0.02, t test).

Conclusion

The changes in optical biometric measurements found in our study were due to the fact that COVID-19 is more frequent and severe in males, SARS-CoV‑2 can attach to the cornea via ACE‑2 receptors, and favipiravir can reach the aqueous humor. To our knowledge, there is no study on this subject to date, and therefore more research is needed to shed light on this topic.
Literatur
1.
2.
Zurück zum Zitat World Health Organization. Infection prevention and control during health care when novel coronavirus (nCoV) infection is suspected: interim guidance. 2020. World Health Organization. Infection prevention and control during health care when novel coronavirus (nCoV) infection is suspected: interim guidance. 2020.
3.
4.
6.
Zurück zum Zitat Seah I, Agrawal R. Can the coronavirus disease 2019 (COVID-19) affect the eyes? A review of coronaviruses and ocular implications in humans and animals. Ocular Immunol Inflamm. 2020;28(3):391–5.CrossRef Seah I, Agrawal R. Can the coronavirus disease 2019 (COVID-19) affect the eyes? A review of coronaviruses and ocular implications in humans and animals. Ocular Immunol Inflamm. 2020;28(3):391–5.CrossRef
7.
Zurück zum Zitat Li JO, Larn DS, Chen Y, Ting DS. Novel coronavirus disease 2019 (COVID-19): the importance of recognising possible early ocular manifestation and using protective eyewear. Br J Ophthalmol. 2020;104(3):297–8.CrossRefPubMed Li JO, Larn DS, Chen Y, Ting DS. Novel coronavirus disease 2019 (COVID-19): the importance of recognising possible early ocular manifestation and using protective eyewear. Br J Ophthalmol. 2020;104(3):297–8.CrossRefPubMed
8.
Zurück zum Zitat Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395(10224):565–74.CrossRefPubMedPubMedCentral Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395(10224):565–74.CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Loon S, Teoh S, Oon L, Se-Thoe S, Ling A, Leo Y, Leong H. The severe acute respiratory syndrome coronavirus in tears. Br J Ophthalmol. 2004;88(7):861–3.CrossRefPubMedPubMedCentral Loon S, Teoh S, Oon L, Se-Thoe S, Ling A, Leo Y, Leong H. The severe acute respiratory syndrome coronavirus in tears. Br J Ophthalmol. 2004;88(7):861–3.CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Yeo C, Kaushal S, Yeo D. Enteric involvement of coronaviruses: Is faecal-oral transmission of SARS-CoV‑2 possible? Lancet Gastroenterol Hepatol. 2020;5(4):335–7.CrossRefPubMedPubMedCentral Yeo C, Kaushal S, Yeo D. Enteric involvement of coronaviruses: Is faecal-oral transmission of SARS-CoV‑2 possible? Lancet Gastroenterol Hepatol. 2020;5(4):335–7.CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Tay MZ, Poh CM, Renia L, MacAry PA, Ng LF. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 2020;20(6):363–74.CrossRefPubMedPubMedCentral Tay MZ, Poh CM, Renia L, MacAry PA, Ng LF. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 2020;20(6):363–74.CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Willcox MD, Walsh K, Nichols JJ, Morgan PB, Jones LW. The ocular surface, coronaviruses and COVID-19. Clin Exp Optom. 2020;103(4):418–24.CrossRefPubMedPubMedCentral Willcox MD, Walsh K, Nichols JJ, Morgan PB, Jones LW. The ocular surface, coronaviruses and COVID-19. Clin Exp Optom. 2020;103(4):418–24.CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Strain WD, Chaturvedi N. The renin-angiotensin-aldosterone system and the eye in diabetes. J Renin Angiotensin Aldosterone Syst. 2002;3(4):243–6.CrossRefPubMed Strain WD, Chaturvedi N. The renin-angiotensin-aldosterone system and the eye in diabetes. J Renin Angiotensin Aldosterone Syst. 2002;3(4):243–6.CrossRefPubMed
14.
Zurück zum Zitat Seah I, Agrawal R. Can the coronavirus disease 2019 (COVID-19) affect the eyes? A review of coronaviruses and ocular implications in humans and animals. Ocul Immunol Inflamm. 2020;28(3):391–5.CrossRefPubMed Seah I, Agrawal R. Can the coronavirus disease 2019 (COVID-19) affect the eyes? A review of coronaviruses and ocular implications in humans and animals. Ocul Immunol Inflamm. 2020;28(3):391–5.CrossRefPubMed
16.
Zurück zum Zitat Siedlecki J, Brantl V, Schworm B, Mayer WJ, Gerhardt M, Michalakis S, et al. COVID-19: ophthalmological aspects of the SARS-CoV 2 global pandemic. Klin Monatsbl Augenheilkd. 2020;237(5):675–80.CrossRefPubMed Siedlecki J, Brantl V, Schworm B, Mayer WJ, Gerhardt M, Michalakis S, et al. COVID-19: ophthalmological aspects of the SARS-CoV 2 global pandemic. Klin Monatsbl Augenheilkd. 2020;237(5):675–80.CrossRefPubMed
17.
Zurück zum Zitat Choudhary R, Kapoor MS, Singh A, Bodakhe SH. Therapeutic targets of renin-angiotensin system in ocular disorders. J Curr Ophthalmol. 2016;29:7–16.CrossRefPubMedPubMedCentral Choudhary R, Kapoor MS, Singh A, Bodakhe SH. Therapeutic targets of renin-angiotensin system in ocular disorders. J Curr Ophthalmol. 2016;29:7–16.CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Sungnak W, Huang N, Becavin C, Berg M, Queen R, Litvinukova M, et al. SARS-CoV‑2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes. Nat Med. 2020;26(5):681–7.CrossRefPubMedPubMedCentral Sungnak W, Huang N, Becavin C, Berg M, Queen R, Litvinukova M, et al. SARS-CoV‑2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes. Nat Med. 2020;26(5):681–7.CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Liu L, Pan X, Shen W, Liu Z, Liu Y, et al. Expression of SARS coronavirus S protein functional receptor—angiotensin-converting enzyme 2 in human cornea and conjunctiva. Chin Opthalmic Res. 2004;22:561–4. Liu L, Pan X, Shen W, Liu Z, Liu Y, et al. Expression of SARS coronavirus S protein functional receptor—angiotensin-converting enzyme 2 in human cornea and conjunctiva. Chin Opthalmic Res. 2004;22:561–4.
23.
Zurück zum Zitat Kayıran AM, Cebeci F, Erdemir VA, Aksoy H, Akdeniz N, Gürel MS. Fluorescence of nails and hair on Wood’s lamp examination in COVID-19 pandemic; undefined effect of favipiravir in humans. Dermatol Ther. 2021;34:e14740. Kayıran AM, Cebeci F, Erdemir VA, Aksoy H, Akdeniz N, Gürel MS. Fluorescence of nails and hair on Wood’s lamp examination in COVID-19 pandemic; undefined effect of favipiravir in humans. Dermatol Ther. 2021;34:e14740.
24.
Zurück zum Zitat Doran MA, Aytogan H, Ayıntap E. Fluorescence of ocular surface in a Covid-19 patient after favipiravir treatment: a case report. Virol J. 2021;18:146.CrossRefPubMedPubMedCentral Doran MA, Aytogan H, Ayıntap E. Fluorescence of ocular surface in a Covid-19 patient after favipiravir treatment: a case report. Virol J. 2021;18:146.CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Megahed SM, Habib AA, Hammad SF, Kamal AH. Experimental design approach for development of spectrofluorimetric method for determination of favipiravir; a potential therapeutic agent against COVID-19 virus: application to spiked human plasma. Spectrochim Acta A Mol Biomol Spectrosc. 2021;249:119241. https://doi.org/10.1016/j.saa.2020.119241.CrossRefPubMed Megahed SM, Habib AA, Hammad SF, Kamal AH. Experimental design approach for development of spectrofluorimetric method for determination of favipiravir; a potential therapeutic agent against COVID-19 virus: application to spiked human plasma. Spectrochim Acta A Mol Biomol Spectrosc. 2021;249:119241. https://​doi.​org/​10.​1016/​j.​saa.​2020.​119241.CrossRefPubMed
26.
Zurück zum Zitat Priya S, Meena MS, Sangumani J, Rathinam P, Priyadharshini CB, Anand VV. Factors influencing the outcome of COVIN-19 patients admitted in a tertiary care hospital, Madurai. A cross sectional study. Clin Epidemiol Glob Health. 2021;10:100705.CrossRefPubMedPubMedCentral Priya S, Meena MS, Sangumani J, Rathinam P, Priyadharshini CB, Anand VV. Factors influencing the outcome of COVIN-19 patients admitted in a tertiary care hospital, Madurai. A cross sectional study. Clin Epidemiol Glob Health. 2021;10:100705.CrossRefPubMedPubMedCentral
Metadaten
Titel
Optical biometric measurements in patients with previous COVID-19 treatment
verfasst von
Tugba Çetinkaya, MD
Muhammed Mustafa Kurt, MD
Publikationsdatum
26.07.2022
Verlag
Springer Vienna
Erschienen in
Spektrum der Augenheilkunde / Ausgabe 4/2023
Print ISSN: 0930-4282
Elektronische ISSN: 1613-7523
DOI
https://doi.org/10.1007/s00717-022-00526-9